- Sai Life Sciences, in partnership with Agility Life Sciences and Centrix Pharma Solutions, has launched an Integrated CMC Partnership to provide end-to-end Chemistry, Manufacturing and Controls (CMC) services for innovator biopharma companies.
- The collaboration offers integrated drug substance and drug product development, supporting efficient progression from preclinical studies to first-in-human clinical trials and beyond.
Sai Life Sciences has announced an Integrated CMC Partnership with Agility Life Sciences and Centrix Pharma Solutions to deliver end-to-end Chemistry, Manufacturing and Controls (CMC) services to innovator biopharma companies. The collaboration combines Sai’s expertise in API development, Agility’s formulation development capabilities, and Centrix’s drug product development and clinical manufacturing experience.
The partnership aims to streamline the CMC value chain by providing integrated planning and execution across drug substance and drug product development. Services span synthetic route scouting, API manufacturing, pre-formulation, and clinical trial material production, enabling faster progression from discovery to first-in-human trials.
“By bringing together our complementary strengths, we can deliver far greater value to innovators—helping them translate ideas into medicines with speed, quality, and efficiency. This partnership reflects our shared commitment to supporting customers on their journey from discovery to the clinic, and ultimately, to patients.”
Krishna Kanumuri, MD & CEO of Sai Life Sciences
The Integrated CMC Partnership offers cross-functional optimisation, reducing duplication, mitigating technical risks, and lowering costs. Teams work collaboratively, ensuring proactive sample transfer, early API evaluation in the drug product process, and a single point of contact to maintain alignment and accountability throughout project execution.
By uniting capabilities across API and drug product development, Sai Life Sciences and its partners aim to provide a more efficient and collaborative pathway for biopharma innovators, enhancing speed, flexibility, and confidence in advancing drug candidates through the development pipeline.
